Staxyn vs cialis: another review - reviews and online consultation

Staxyn vs cialis: another review

Opinion: Staxyn vs cialis: another review

Erectile dysfunction is a common clinical entity that affects mainly men older than 40 years. In addition to the classical causes of erectile dysfunction, such as diabetes mellitus and hypertension, several common lifestyle factors, such as obesity, limited or an absence of physical exercise, and lower urinary tract symptoms, have been linked to the development of erectile dysfunction. Substantial steps have been taken in the study of the association between erectile dysfunction and cardiovascular disease.



Erectile dysfunction is a strong predictor for coronary artery disease, and cardiovascular assessment of a non-cardiac patient presenting with erectile dysfunction is now recommended. Substantial advances have occurred in the understanding of the pathophysiology of erectile dysfunction that ultimately led to the development of successful oral therapies, namely the phosphodiesterase type 5 inhibitors. However, oral phosphodiesterase type 5 inhibitors have limitations, and present research is thus investigating cutting-edge therapeutic strategies including gene and cell-based technologies with the aim of discovering a cure for erectile dysfunction.Staxyn vs cialis


Staxyn dosage


While in the older article we compare vardenafil vs cialis, this one is dedicated to another popular drug called Staxyn. We searched PubMed for papers published in English between 1980 and March, 2012, with the terms “erectile dysfunction” and “impotence”, “diagnosis”, “treatment”, “epidemiology”, “physiology”, and “pathophysiology”. We also reviewed recent and past textbooks. We mainly focused on publications in the past 5 years; however, we did not ignore landmark relevant articles. Other relevant articles identified by staxyn 10 mg reviews of the reference lists of selected articles were also included. We also reviewed abstracts from relevant scientific meetings. The diagnosis and treatment sections were written according to the guidelines and recommendations of the International Society for Sexual Medicine, the American Urological Association, and the European Association of Urology.


Substantial advances in our understanding of the physiology of erection and the pathophysiology of erectile dysfunction led to the development of the first successful group of oral treatments for erectile dysfunction— PDE5-Is. Erectile dysfunction is now recognised as an early predictor of CAD. Despite these advances, there is still a great need for more effective therapeutic drugs that can provide long-lasting improvement for erectile dysfunction. Future promising therapeutic strategies, including gene and cell-based therapy, might lead to a cure for erectile dysfunction.